Variant Bio, Inc. — Form D/A
Variant Bio, Inc. of SEATTLE, WA, a company, filed a Form D amendment with the SEC on 2021-11-17. The offering totals $105.0M, of which $105.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-11-17
- Form: D/A
- Accession: 0001790599-21-000003
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $105.0M
- Amount sold: $105.0M
- Investors: 12
- Date of first sale: 2021-10-29
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-419841
Issuer
- Name: Variant Bio, Inc.
- CIK: 0001790599
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 1616 EASTLAKE AVE E, SUITE 208, SEATTLE, WA, 98102
- Phone: 206-719-6382
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Stephane Castel | Director | Seattle, WA |
| Andrew Farnum | Director | Seattle, WA |
| Bob More | Director | Venice, CA |
| Stuart Nagae | Director | Seattle, WA |
| Julie Sunderland | Director | CAMBRIDGE, MA |
| Elena Viboch | Director | Menlo Park, CA |
| Josh Wolfe | Director | New York, NY |
| Stephane Castel | Executive Officer | Seattle, WA |
| Andrew Farnum | Executive Officer | Seattle, WA |
| Josh Wolfe | Executive Officer | New York, NY |
| Adam Goulburn | Director | New York, NY |
| Kaja Wasik | Director | New York, NY |
| Kaja Wasik | Executive Officer | New York, NY |
| Akhila Kosaraju | Director | New York, NY |
| Akhila Kosaraju | Executive Officer | New York, NY |
Other filings by this issuer (3)
More